Oncodrug is an integrated drug discovery biotech developing small-molecule and biologic therapeutics for oncology, fibrotic, and metabolic diseases with high unmet need. The company focuses on underexplored targets including lysyl oxidase (LOX), ALDH1A3, and PKN2 inhibitors, plus a viral immunotherapy platform, with in-house capabilities spanning target validation through candidate nomination.
Funding
Funding not disclosed
Founders
Product
Problem
Fibrotic diseases, certain metabolic disorders, and many cancers remain difficult to treat due to resistance mechanisms and a lack of effective therapies targeting disease-driving pathways. Existing treatments often fail to address key processes such as collagen crosslinking in fibrosis, retinoic acid receptor dysregulation in type II diabetes, or resistance to RAS and EGFR inhibitors in cancer.
Solution
Oncodrug is a multi-disciplinary drug discovery biotech advancing a pipeline of small-molecule and biologic assets against underexplored targets of high medical importance. The company develops LOX inhibitors to block collagen crosslinking in fibrotic diseases and cancer treatment resistance, ALDH1A3 inhibitors to restore pancreatic β-cell function and overcome therapy resistance, PKN2 inhibitors to address RAS/EGFR inhibitor resistance and heart failure, and a viral immunotherapy platform with a unique combination of mechanisms of action. Oncodrug operates fully integrated in-house capabilities including assay development, medicinal chemistry, in silico chemistry, cell biology, bioanalysis, pharmacokinetics, and in vivo efficacy studies across oncology, fibrosis, and diabetes models.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking partnerships or licensing opportunities for novel drug discovery assets, as well as investors interested in funding preclinical-stage therapeutics for oncology, fibrotic, and metabolic diseases.
Features
- LOX inhibitor program targeting collagen crosslinking, a key driver of fibrosis and cancer treatment resistance
- ALDH1A3 inhibitor program modulating the retinoic acid receptor pathway for type II diabetes and cancer therapy sensitization
- PKN2 inhibitor program addressing RAS and EGFR inhibitor resistance in targeted therapies and heart failure
- Viral immunotherapy platform combining multiple mechanisms of action for cancer treatment
- Integrated capabilities spanning assay development, medicinal chemistry, in silico chemistry, cell biology, bioanalysis, biomarkers, in vivo pharmacokinetics, and efficacy studies
- In-house expertise covering oncology, fibrosis, and diabetes disease models for preclinical validation